

AGREED BOARD ORDER #2024-03741

RE: IN THE MATTER OF
NOVA SPECIALTY PHARMACY
(PHARMACY LICENSE #34701)

BEFORE THE TEXAS STATE
BOARD OF PHARMACY

On this day came on to be considered by the Texas State Board of Pharmacy (Board) the matter of pharmacy license number 34701 issued to Nova Specialty Pharmacy (Respondent), 3815 West Grand Parkway North, Suite 220, Katy, Texas 77449.

By letter dated February 10, 2025, the Board gave preliminary notice to Respondent of its intent to take disciplinary action. This action was taken as a result of an investigation which produced evidence indicating that Respondent may have violated:

Sections 565.001(a)(1), (2), (12) and (13); and 565.002(a)(3), (4) and (8) of the Texas Pharmacy Act, TEX. OCC. CODE ANN. Title 3, Subtitle J (2023); and

Sections 281.7(a)(6) and (13); 291.31(15); 291.32(a)(2)(E), (G) and (H); 291.32(c)(1)(E); 291.34(a)(1); 291.34(b)(9); 291.34(e)(1)(C), (D) and (E); 291.34(e)(2)(A), (B), (C), (G), (H) and (I); 291.133(a); and 295.3 of the Texas Pharmacy Board Rules, 22 TEX. ADMIN. CODE (2024), in that allegedly:

COUNTS

(1)-(43) From on or about January 18, 2024, through on or about June 28, 2024, Obiechina Nnamdi Ezekwesili, while acting as an employee (pharmacist-in-charge) of Nova Specialty Pharmacy, 3815 West Grand Parkway North, Suite 220, Katy, Texas 77493 (previously located at 2651 East Broad Street, Suite 101, Mansfield, Texas 76063), allowed Nova Specialty Pharmacy to unlawfully engage in the operation of a pharmacy, in that Nova Specialty Pharmacy dispensed and sold prescription drugs to patients in the following states where Nova Specialty Pharmacy did not possess a license from the respective state's board of pharmacy or other state licensing entity necessary to operate in that state as a pharmacy or wholesale facility:

Count	State	Number of Dispensed Prescriptions
(1)	Alabama	465
(2)	Alaska	42
(3)	Arkansas	351
(4)	Arizona	265
(5)	California	5,613
(6)	Connecticut	147
(7)	Delaware	62
(8)	District of Columbia	64
(9)	Florida	1,160

(10)	Georgia	424
(11)	Hawaii	95
(12)	Iowa	62
(13)	Idaho	63
(14)	Illinois	424
(15)	Indiana	182
(16)	Kansas	115
(17)	Kentucky	303
(18)	Louisiana	37
(19)	Maryland	241
(20)	Minnesota	179
(21)	Missouri	219
(22)	Montana	67
(23)	Nebraska	75
(24)	Nevada	176
(25)	New Hampshire	36
(26)	New Jersey	352
(27)	New Mexico	25
(28)	New York	678
(29)	North Carolina	500
(30)	North Dakota	70
(31)	Ohio	328
(32)	Oklahoma	106
(33)	Oregon	141
(34)	Pennsylvania	383
(35)	Rhode Island	39
(36)	South Carolina	629
(37)	South Dakota	31
(38)	Tennessee	236
(39)	Utah	134
(40)	Washington	316
(41)	West Virginia	45
(42)	Wisconsin	206
(43)	Wyoming	30

Total Number of Transactions: 15,443

- (44) On or about November 9, 2024, Obiechina Nnamdi Ezekwesili, while acting as an employee (pharmacist-in-charge) and as a corporate managing officer of Nova Specialty Pharmacy, 3815 West Grand Parkway North, Suite 220, Katy, Texas 77493 (previously located at 2651 East Broad Street, Suite 101, Mansfield, Texas 76063), failed to keep and maintain complete and accurate records, or failed to supply records within 72 hours of a request made by an authorized agent of the Texas State Board of Pharmacy (Board). Specifically, on November

6, 2024, Board staff requested compounding and dispensing records of prescription number 64651, and the pharmacy did not produce any dispensing records to comply with this request.

An informal conference was held via videoconference on April 1, 2025, with Obiechina Nnamdi Ezekwesili, R.Ph., Managing Officer, Echo Health LLC, and Pharmacist-in-Charge, on behalf of Respondent, and Luis Lanz, Legal Counsel for Respondent, in attendance. The informal conference was heard by a Board panel comprised of: Donnie Lewis, R.Ph., Board Member; Donna Montemayor, R.Ph., Board Member; and Daniel Carroll, Pharm.D., Executive Director/Secretary; with Megan G. Holloway, General Counsel. Mary Moretti, Assistant Litigation Counsel, was also in attendance.

By appearing at the informal conference and by signing this Order, Obiechina Nnamdi Ezekwesili, on behalf of Respondent, and Respondent's counsel neither admit nor deny the truth of the matters previously set out in this Order, and agree that the Board has jurisdiction in this matter and waive the right to notice of hearing, formal administrative hearing, and judicial review of this Order.

The parties acknowledge that this Order resolves the allegations set forth herein, and agree to the terms and conditions set forth in the ORDER OF THE BOARD below.

ORDER OF THE BOARD

THEREFORE, PREMISES CONSIDERED, the Board does hereby ORDER that:

- (1) Respondent shall pay an administrative penalty of forty-three thousand five hundred dollars (\$43,500) due one hundred twenty (120) days after the entry of this Order.
- (2) Respondent shall develop and implement policies and procedures to ensure compliance with pharmacy and pharmacist licensure requirements from licensing entities in states where Respondent operates or seeks to operate as a pharmacy or wholesale facility. A written report of such policies and procedures shall be submitted to Board staff within one hundred twenty (120) days after the entry of this Order.
- (3) Respondent shall be responsible for all costs relating to compliance with the requirements of this Order.
- (4) Respondent shall allow Board staff to directly contact Respondent on any matter regarding the enforcement of this Order.

- (5) Failure to comply with any of the requirements in this Order constitutes a violation and shall be grounds for further disciplinary action. The requirements of this Order are subject to the Texas Pharmacy Act, TEX. OCC. CODE ANN., Title 3, Subtitle J (2023), and Texas Pharmacy Board Rules, 22 TEX. ADMIN. CODE (2025).


And it is so ORDERED.

THIS ORDER IS A PUBLIC RECORD.


SIGNED AND ENTERED ON THIS 5th day of August, 2025.



MEMBER, TEXAS STATE BOARD OF PHARMACY

ATTEST:


Daniel Carroll, Pharm.D.
Executive Director/Secretary
Texas State Board of Pharmacy

APPROVED AS TO FORM AND AGREED TO:


Obiechina Nnamdi Ezekwesili, R.Ph., Managing Officer, Echo Health LLC
On behalf of Nova Specialty Pharmacy


Luis Lanz Legal Counsel for Nova Specialty Pharmacy
Quarles & Brady LLP
One Renaissance Square
Two North Central Avenue, Suite 600
Phoenix, Arizona 85004

APPROVED AS TO FORM:


Megan G. Holloway, General Counsel
Texas State Board of Pharmacy